Approval Probability
TA Base Rate
Adjusted LOA
ML Risk
Panzem NCD · 3 trials · 3 indications
| Arm | Type | Description |
|---|---|---|
| 1 | EXPERIMENTAL | - |
| A | EXPERIMENTAL | - |
| B | EXPERIMENTAL | - |
| Name | Type | Description |
|---|---|---|
| Panzem NCD | DRUG | 2000 mg q8h, continuous dosing in 28 day cycles |
| Temozolomide | DRUG | Fixed dose |
| Panzem® NCD | DRUG | NCD suspension, 1500 mg TID daily for 6 week cycles |
| Sunitinib Malate | DRUG | Sunitinib Malate, highest tolerated dose (patient's current dose), daily oral administration for 4 weeks, with 2 week break in 6 week cycle |
Inclusion Criteria: 1. A histologically confirmed diagnosis of a recurrent/progressive primary WHO grade IV malignant glioma (glioblastoma multiforme or gliosarcoma). Patients with recurrent disease whose diagnostic pathology confirmed WHO grade IV malignant glioma (glioblastoma multiforme or glios...
Panzem NCD is an investigational small molecule being studied for the treatment of metastatic renal cell carcinoma, prostate cancer, and recurrent glioblastoma multiforme. It is being developed by CASI Pharmaceuticals, Inc. (NASDAQ: CASI) and is currently in Phase 2 clinical development.
The specific molecular target of Panzem NCD has not been disclosed in available information. It is a small molecule oncology agent being investigated for its anti-cancer activity in multiple tumor types, including metastatic renal cell carcinoma, prostate cancer, and recurrent glioblastoma multiforme.
Panzem NCD is being developed by CASI Pharmaceuticals, Inc., a biopharmaceutical company traded on NASDAQ under the ticker symbol CASI. The company is conducting clinical trials of this investigational drug in oncology indications.
Panzem NCD is in Phase 2 clinical development. It is an investigational drug and has not been approved by regulatory authorities. All completed clinical trials for Panzem NCD were Phase 2 studies, and the drug remains under investigation for its safety and efficacy.
Panzem NCD has completed three Phase 2 clinical trials: NCT00394810 in hormone-refractory prostate cancer, NCT00444314 in metastatic renal cell carcinoma alone and with sunitinib, and NCT00481455 in recurrent glioblastoma multiforme with temozolomide. All trials were conducted in the United States.
Panzem NCD is a specific formulation of the drug Panzem, using nanocrystal colloidal dispersion technology. The clinical trials listed under Panzem NCD evaluate this particular formulation in prostate cancer, renal cell carcinoma, and glioblastoma multiforme.